12:00 AM
 | 
Nov 07, 2005
 |  BioCentury  |  Finance

Comparing panitumumab

Comparing panitumumab

Company Product (Status) Target Trial (Patients) Overall survival Progression-free survival (PFS) Objective response rate (ORR)
Abgenix/ Amgen Panitumumab (Ph III for metastatic colorectal cancer) EGFR Ph III (463) Not available Significantly improved(p<0.000000001) (primary endpoint) Significantly improved; no details disclosed (secondary endpoint)

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >